February 11, 2026- Thermo Fisher Scientific announced a strategic data collaboration with Datavant, the data collaboration platform trusted for healthcare, to make it easier for pharmaceutical and biotech companies to connect real-world data with clinical research—helping them generate stronger evidence, faster. Thermo Fisher’s PPD™ clinical research business and Datavant will enable secure connection and analysis of real-world data (RWD), spanning RWD enrichment of randomized clinical trials, PPD™ CorEvitas™ Clinical Registries and PPD™ Evidera™ solutions.
Datavant enables privacy-preserving tokenization and linkage of patient-level data across more than 350 RWD partners and 80,000 U.S. hospitals and clinics. With this technology, Thermo Fisher’s PPD clinical research business can securely connect de-identified research datasets and retrieve consented electronic medical record (EMR) data for bespoke RWD generation. Integrating Datavant’s encrypted token technology within Thermo Fisher’s RWD infrastructure will provide biopharmaceutical and biotech customers with access to enhanced linked patient data and advanced analytics to design more connected studies, improve recruitment and accelerate evidence generation, ultimately supporting better patient outcomes.
The collaboration builds on Thermo Fisher’s broader investments in digital innovation, including its strategic collaboration with OpenAI, to deliver more value and greater scientific innovation to life sciences customers.